The clinical and demographic characteristics of nonneuronopathic Gaucher Disease in 887 children at diagnosis

Archives of Pediatrics and Adolescent Medicine

Volumn 160, Issue 6, 2006, Pages 603-608

  Kaplan, Paige ^a,d   Andersson, Hans C ^b   Kacena, Katherine A ^c   Yee, John D ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENZYME CORPORATION   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BONE DISEASE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; ENZYME REPLACEMENT; ETHNOLOGY; FEMALE; GAUCHER DISEASE; GENOTYPE; GROWTH RETARDATION; HEPATOMEGALY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTOPENIA;

ADOLESCENT; ANEMIA; BONE DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; GAUCHER DISEASE; GROWTH DISORDERS; HEPATOMEGALY; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 33744957572     PISSN: 10724710     EISSN: 10724710     Source Type: Journal    
DOI: 10.1001/archpedi.160.6.603     Document Type: Article

References (17)

1. Brady RO, Kanfer J, Shapiro D. Metabolism of glucocerebrosides. J Biol Chem. 1965;240:39-42.
2. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill Co; 2001:3635-3668.
3. Zevin S, Abrahamov A, Hadas-Halpern I, et al. Adult-type Gaucher disease in children. Q J Med. 1993;86:565-573.
4. Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr. 1996;129:149-153.
5. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency. N Engl J Med. 1991;324:1464-1470.
6. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with non-neuronopathic Gaucher disease after 2 to 5 years of treatment. Am J Med. 2002;113:112-119.
7. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.
8. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher Registry. Arch Intern Med. 2000;160:2835-2843.
9. Ludwig J. Current Methods of Autopsy Practice. Philadelphia, Pa: WB Saunders Co; 1979.
10. Elstein D, Hadas-Halpern I, Azuri Y, Abrahamov A, Bar-Ziv Y, Zimran A. Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease. J Ultrasound Med. 1997;16:209-211.
11. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;(314):1-27.
12. Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. New York, NY: John Wiley & Sons Inc; 1999.
13. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. 2nd ed. Cary, NC: SAS Institute Inc; 2000.
14. Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S. Guidelines for human gene nomenclature. Genomics. 2002;79:464-470.
15. Weinreb N, Deegan P, Kacena K, Mistry P, Pastores GM, vom Dahl S. Life expectancy in type 1 (non-neuronopathic) Gaucher disease. http://www.ashg.org/ cgi-bin/ashg05s/ashg05. Accessed December 9, 2005.
16. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with non-neuronopathic Gaucher disease: consensus recommendations. J Pediatr. 2004;144:112-120.
17. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4)(suppl 5):4-14.